Methods for treating or preventing an inflammatory or metabolic condition by inhibiting JNK

Details for Australian Patent Application No. 2004224302 (hide)

Owner Signal Pharmaceuticals, LLC

Inventors Satoh, Yoshitaka; Bhagwat, Shripad S.

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-A-2004224302

PCT Pub. Number WO2004/084901

Priority 10/395,811 24.03.03 US

Filing date 24 March 2004

Wipo publication date 7 October 2004

International Classifications

A61K 031/506 - not condensed and containing further heterocyclic rings

C07D 239/42 Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings

A61P 003/04 Drugs for disorders of the metabolism

A61K 031/5377

A61P 003/10 Drugs for disorders of the metabolism

Event Publications

27 October 2005 PCT application entered the National Phase

  PCT publication WO2004/084901 Priority application(s): WO2004/084901

22 October 2009 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004224303-Methods for treating inflammatory conditions or inhibiting JNK

2004224294-Production of 5-methyl-N-(methyl aryl)-2-pyrrolidone, 5-methyl-N-(methyl cycloalkyl)-2-pyrrolidone and 5-methyl-N-alkyl-2-pyrrolidone